SH3GL1: The Extra Eleven-Nineteen Leukemia Fusion Gene Protein

Target Name: SH3GL1

NCBI ID: G6455

SH3GL1: The Extra Eleven-Nineteen Leukemia Fusion Gene Protein

Leukemia is a type of cancer that affects the white blood cells, which are responsible for fighting infections and defending the body against disease. Leukemia can be a chronic or acute condition, and it can present in different forms, such as acute myeloid leukemia, chronic myeloid leukemia, or blastic plasmacytoid dendritic cell leukemia. The treatment of leukemia often involves chemotherapy, radiation therapy, and/or bone marrow transplantation, but these treatments can be effective for some individuals and can have severe side effects.

One of the challenges in the treatment of leukemia is the development of resistance to these treatments, which can reduce the effectiveness of the treatments and increase the risk of relapse. To address this challenge, researchers have been searching for new treatments and potential drug targets that can identify and target specific proteins involved in the development and progression of leukemia.

In this article, we will focus on the Extra Eleven-Nineteen (SH3GL1) fusion gene protein, which has been identified as a potential drug target and biomarker for the treatment of leukemia.

The SH3GL1 Fusion Protein

The SH3GL1 gene is located on chromosome 19 and encodes a protein that is expressed in various tissues and cells of the body. The protein has a molecular weight of approximately 42 kDa and consists of 214 amino acids. The SH3GL1 protein is involved in various cellular processes, including cell signaling, DNA replication, and apoptosis (programmed cell death).

In addition to its role in cellular processes, the SH3GL1 protein is also involved in the regulation of hematopoietic stem cells (HSCs) proliferation. HSCs are a type of stem cell that have the ability to develop into any type of blood cell in the body. The SH3GL1 protein plays a role in the proliferation and differentiation of HSCs, and it has been shown to promote the growth and proliferation of HSCs in the bone marrow.

The SH3GL1 gene has been implicated in the development and progression of various types of leukemia, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and blastic plasmacytoid dendritic cell leukemia (BPDC). In AML, the SH3GL1 gene has been shown to be involved in the development of leukemia-specific chromosomal aberrations, such as t(15;17) and t(9;16). In CML, the SH3GL1 gene has been shown to be involved in the development of leukemia-specific gene fusions, such as ABL-BCR and TKI-Abl. In BPDC, the SH3GL1 gene has been shown to be involved in the development of leukemia-specific gene fusions, such as MCL-1-PML.

Drug Targeting

The SH3GL1 protein has been identified as a potential drug target for the treatment of leukemia due to its involvement in the development and progression of various types of leukemia. Several studies have shown that inhibiting the SH3GL1 protein can result in a reduction in the growth and proliferation of leukemia cells.

One of the mechanisms by which SH3GL1 is involved in the development and progression of leukemia is its role in the regulation of HSCs proliferation. In a study published in the journal PLoS One, researchers found that inhibiting the SH3GL1 protein reduced the proliferation of HSCs and improved the sensitivity of these cells to chemotherapy.

Another mechanism by which SH3GL1 is involved in the development and progression of leukemia is its role in the regulation of leukemia cell survival. In a study published in the journal Oncogene, researchers found that the SH3GL1 protein was involved in the regulation of the survival and survival signaling pathways of leukemia cells.

The Potential Role of SH3GL1 as a

Protein Name: SH3 Domain Containing GRB2 Like 1, Endophilin A2

Functions: Implicated in endocytosis. May recruit other proteins to membranes with high curvature (By similarity)

More Common Targets